Updating the ICF After a Protocol Amendment
By Kamila Kiriek, MD, PhD, Chief Medical Officer, Skaldi
When a protocol amendment changes what participants will experience, are asked to do, or need to know, the informed consent form is revised to match. The revised form is reviewed and approved by the IRB or ethics committee before it is used, new participants consent on the approved version, and the investigator and sponsor decide, with the committee's review, what participants already in the study are told and whether they are asked to consent again.
This article covers the practical side: how to find the consent wording an amendment affects, how to draft and review the revision, and how to keep the record straight. Whether a given change requires re-consent, and how quickly, is not something an article can decide. It depends on the change, on the participants and on the committee, and the last section says who makes that call.
When the ICF needs to change
A consent form restates the protocol in plain language. It needs attention whenever an amendment touches something the form describes or relies on:
- visits, procedures, samples, or how long participation lasts
- eligibility, where the form explains who can take part
- the investigational product: dose, schedule, route, or how it is supplied
- known or possible risks and discomforts, and the measures taken to reduce them
- alternatives, expected benefits, costs, payments or compensation
- how data and samples are used, stored or shared
- contact details, and the study's title or version references
The underlying rule is long-standing. ICH E6 requires that the written consent form and other information given to participants be revised whenever important new information becomes available that may be relevant to their consent, that the revision receive the committee's approval before use, and that participants be informed in a timely manner of information that may affect their willingness to continue. In the United States, 21 CFR 50.25 lists the elements of informed consent, including, where appropriate, a statement that significant new findings that may relate to a participant's willingness to continue will be provided; 21 CFR 56.108(a)(4) requires IRB approval before changes to approved research are initiated, except where necessary to eliminate apparent immediate hazards. In the European Union, Chapter V of Regulation (EU) No 536/2014 sets out the requirements for informed consent, and a change to the consent documents is submitted with the modification under Chapter III of that regulation.
Not every amendment changes the form. An amendment confined to laboratory handling or to statistical methods may leave the participant's experience untouched. The point of the check is to be able to show that the form was compared with the amendment, whatever the answer.
Steps
1. Start from the amended protocol, not from the old ICF
List what changed in the protocol, one change per line, with the section and the previous and new wording. Then go to the consent form with that list. Reading the form first and asking "does anything here look wrong?" finds the obvious sentences and misses the quiet ones.
2. Find every place the form states or assumes the changed fact
Consent forms repeat themselves on purpose. A visit schedule can appear in a summary at the front, in the section on what happens during the study, in a table of visits, in the section on risks of blood draws, and again in the section on time commitment. Check all of them, and check the wording as a participant would read it: forms say "three visits to the clinic", not "Days 1, 8 and 29".
Take an illustration. A protocol's Schedule of Assessments had clinic visits and blood samples on Days 1 and 29; the amendment adds Day 8. The consent form's section on what will happen says: "After your Day 1 visit, your next clinic visit will be on Day 29. Blood samples will be taken on Days 1 and 29." Both sentences are affected. A proposed revision would read: "After your Day 1 visit, you will return to the clinic on Days 8 and 29. Blood samples will be taken on Days 1, 8 and 29."
3. Separate what the source supports from what it leaves open
The amended schedule supports the new dates. It does not say how much blood is taken on Day 8 or how long the visit lasts. If the form states a total blood volume or a total time commitment, those statements may now be wrong, but the amendment alone cannot tell you the new figures. Write that down as an open question for the person who has the information. Do not fill the gap with an estimate, and do not leave the old figure in place without asking.
This distinction is the most useful habit in consent revision. Wording that follows directly from the source can be drafted now. Wording that needs a fact the source does not contain waits for that fact.
4. Draft the revision so that a reviewer sees the change
For each affected passage, keep four things together: the current wording, the proposed wording, the protocol section it follows from, and one sentence on why. A tracked-changes file shows what moved; it does not show why, and a reviewer who has to open the protocol to work that out will either skip the check or repeat your work.
Keep the language at the level of the rest of the form. A revision that drops a protocol sentence into participant text ("PK sampling at Day 8") creates a readability problem that the committee will send back.
5. Check the rest of the participant-facing set
The same change usually applies to short-form or summary consents, information sheets, visit cards and diaries, and to every translation. Where the study enrols minors or adults unable to consent independently, assent forms and any information materials for their legal representatives are checked as well. Translations are revised from the approved revised text, not from the tracked changes, and their version identifiers are kept in step with the source form.
6. Review, then submit
The medical monitor or responsible physician reviews the content, regulatory affairs reviews the submission, and clinical operations checks that sites can use the form as written. The revised form then goes to the IRB or ethics committee, with the amended protocol where the committee reviews them together. Sites do not use the revised form until they hold the approval.
7. Put the approved version into use and record it
Each site needs the approved form, the date from which it applies, and instruction on what to do with participants at each stage: not yet consented, in screening, on treatment, in follow-up. Superseded versions are withdrawn. The site file and the Trial Master File hold the approved form, the approval, and, for each participant, the version signed and the date.
Common mistakes
- Updating the visit table and missing the prose. Or the reverse. The form is consistent only when every statement of the fact agrees.
- Carrying over totals. Total blood volume, number of visits and length of participation are derived figures. They are easy to leave untouched when one visit is added.
- Describing the change instead of the study. A participant reading the revised form for the first time should see the study as it now is, without references to what it used to be. A separate summary of changes can accompany the form for participants who are re-consenting, if the committee agrees.
- Letting versions drift. A form dated before the protocol version it claims to reflect, or translations with a different version number from their source, are among the simplest findings to make and to avoid.
- Using the new form early. Draft forms circulated for review sometimes reach a clinic. Mark drafts clearly and control distribution.
- Treating "no change needed" as no record needed. If the form was checked and found unaffected, say so, with the reason.
What remains a decision for the investigator, the sponsor and the committee
A careful revision process produces an accurate form and a clear list of what changed. It does not settle:
- Whether participants already enrolled must consent again, be informed in another way, or need no new information. This turns on whether the change may affect their willingness to continue and on local requirements. The sponsor and investigator propose; the IRB or ethics committee reviews.
- How and when participants are told. Some information should reach participants before the revised form is approved, for example a new safety finding. The investigator and the committee decide how that is done and documented.
- Whether the change alters the balance of risk and benefit. This is a medical judgement.
- Whether the amendment is substantial for regulatory purposes. Regulatory affairs makes that classification under the rules of each region.
What the process can do is make sure those decisions are taken with the facts in front of the people responsible: exactly which sentences change, what each follows from, and what is still unknown.
Related reading
- Protocol amendment impact assessment: which documents to check
- Managing informed consent updates during ongoing trials
- Managing protocol amendments across clinical documentation
- A reviewable change record for clinical documents
Sources
- ICH E6(R3), Guideline for Good Clinical Practice (informed consent of trial participants).
- 21 CFR 50.25, Elements of informed consent; 21 CFR 56.108(a)(4), IRB functions and operations.
- Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use, Chapter III and Chapter V.
🔄 Skaldi connects a protocol amendment to proposed, source-linked revisions in the linked ICF, with expert review.
See the amendment exampleProtocol changed. Documents in step.
When a source changes, every affected document follows. Pilots start with protocol amendments.